細胞培養市場分析及至2035年預測：依類型、產品、服務、技術、應用、過程、最終用戶、設備、模式分類

全球細胞培養市場預計將從2025年的330億美元成長到2035年的913億美元，CAGR為10.7%。生物製藥、疫苗、細胞療法和再生醫學等領域對細胞培養技術的需求不斷成長，是推動細胞培養市場成長的主要動力。根據美國食品藥物管理局（FDA）生技藥品評估與研究中心（CBER）發布的2024會計年度報告，FDA加大對快速成長的細胞和基因治療領域的支持力度，自2023年8月治療產品管理局（ATP）重組以來，已批准了10種針對罕見疾病的新型細胞和基因療法。這凸顯了對先進細胞培養技術日益成長的需求。哺乳動物細胞培養系統、生物加工平台和可擴展生產解決方案的日益普及，也進一步加速了市場成長。

細胞培養市場的「類型」細分包括原代細胞培養、繼代細胞培養、系列細胞株、幹細胞培養和3D細胞培養。由於系列細胞株培養和3D細胞培養在生物製藥生產、藥物研發和疾病建模中的應用日益廣泛，因此它們是成長最快的細分市場之一。系列細胞株在大規模生產上具有可擴展性、可重複性和成本效益等優勢，而3D細胞培養則能建構更精確的生理模型。隨著再生醫學、組織工程和個人化醫療研究的不斷深入，幹細胞培養的重要性也日益凸顯。

細胞培養市場的終端使用者包括製藥和生物技術公司、學術和研究機構、醫院和診斷實驗室等。製藥和生物技術公司憑藉其在生物製藥生產、疫苗、基因治療和藥物研發等領域廣泛的細胞培養應用，正引領市場發展。學術和研究機構透過在細胞生物學、癌症研究和再生醫學領域的研究，為市場做出了重要貢獻。醫院和診斷實驗室則將細胞培養技術應用於臨床檢測和疾病研究。對先進療法和精準醫療的持續投入，進一步推動了整個終端用戶市場的成長。

區域概覽

到2025年，北美將佔據全球細胞培養市場最大佔有率，這主要得益於其成熟的生物技術和製藥產業、先進的研究基礎設施以及對生命科學領域的巨額投資。該地區匯聚了許多領先的生物製藥公司、學術研究機構和合約研究組織，它們廣泛利用細胞培養技術進行藥物發現、疫苗研發、再生醫學和生物製藥生產。政府對生物醫學研究的大力投入、3D細胞培養系統的普及以及對單株抗體和細胞療法日益成長的需求，都進一步推動了市場成長。此外，培養基、反應器和自動化細胞培養平台的持續創新，也鞏固了北美在全球細胞培養市場的主導地位。

在亞太地區，生物製藥產業的快速擴張、生物技術研發投入的增加以及生物製藥生產能力的提升，預計將推動細胞培養市場達到最高成長率。中國、印度、日本、韓國和新加坡等國家正透過政府主導的措施、擴大研究設施以及加大對細胞療法、疫苗生產和再生醫學的投資，加強其生命科學基礎設施建設。合約研發生產機構（CDMO）的日益增加、臨床研究活動的活性化以及對生物相似藥需求的成長，進一步加速了市場擴張。此外，低廉的生產成本、高素質的科研人才以及有利的政府政策，使得亞太地區在整個預測期內成為成長最快的區域市場。

主要趨勢和促進因素

3D細胞培養和先進細胞培養技術的應用日益廣泛

細胞培養市場正呈現強勁的趨勢，即採用先進的3D細胞培養模型、類器官和微生理系統，這些模型與傳統的2D培養相比，能夠更精確地模擬人體生物反應。這些技術正日益廣泛地應用於藥物研發、毒性測試、再生醫學和個人化醫療等領域。製藥和生物技術公司正投資於創新的細胞培養平台，例如自動化反應器、無血清培養基和可擴展的生產系統，以提高研究效率和治療藥物的生產能力。對可靠的臨床前模型和生技藥品日益成長的需求，加速下一代細胞培養解決方案的普及應用。

生物製藥、細胞療法和疫苗生產的需求不斷成長

生物製藥、細胞療法、疫苗和再生醫學產品日益成長的需求是細胞培養市場的主要驅動力。單株抗體、重組蛋白、基因療法和細胞療法的擴展，增加了對高效且可擴展的細胞培養系統的需求。製藥和生物技術公司投資研發先進的培養基、一次性反應器和高性能細胞培養技術，以支援大規模生產。此外，癌症生物學、幹細胞研究和藥物發現領域的研究活動活性化，進一步擴大了細胞培養技術的應用範圍。生物製藥產品線的擴展和全球醫療保健領域投資的增加，將繼續推動市場成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機會
• 市場限制因素
• 年複合成長率分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 原代細胞培養
  • 繼代細胞培養
  • 連續性細胞株
  • 幹細胞培養
  • 3D細胞培養
  • 其他
• 市場規模及預測：依產品分類
  • 培養基
  • 血清
  • 試劑
  • 反應器
  • 文化體系
  • 冷凍保存裝置
  • 消耗品
  • 其他
• 市場規模及預測：依服務分類
  • 細胞株構建
  • 細胞庫
  • 細胞培養污染檢測
  • 其他
• 市場規模及預測：依技術分類
  • 2D細胞培養
  • 3D細胞培養
  • 微載體培養
  • 灌注培養
  • 其他
• 市場規模及預測：依應用領域分類
  • 生物製藥生產
  • 組織工程與再生醫學
  • 癌症研究
  • 基因治療
  • 藥物研發
  • 幹細胞研究
  • 其他
• 市場規模及預測：依最終用戶分類
  • 製藥和生物技術公司
  • 學術和研究機構
  • 醫院/診斷實驗室
  • 其他
• 市場規模及預測：依過程分類
  • 上游過程
  • 下游過程
  • 其他
• 市場規模及預測：依設備分類
  • 培養箱
  • 離心機
  • 生物安全櫃
  • 移液設備
  • 其他
• 市場規模及預測：依模式
  • 黏附培養
  • 懸浮培養
  • 其他

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲國家
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 其他亞太國家
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲國家
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲國家

第6章 市場策略

• 供需差距分析
• 貿易和物流限制
• 定價和成本利潤率趨勢
• 市場滲透率
• 消費者分析
• 監管概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要公司的策略

第8章 公司簡介

• Thermo Fisher Scientific
• Merck KGaA
• GE Healthcare
• Lonza Group
• Corning Incorporated
• Sartorius AG
• Eppendorf AG
• Becton Dickinson and Company
• Danaher Corporation
• Fujifilm Holdings Corporation
• Agilent Technologies
• Bio-Rad Laboratories
• Miltenyi BIoTec
• Promega Corporation
• Takara Bio
• HiMedia Laboratories
• InvivoGen
• STEMCELL Technologies
• Greiner Bio-One International
• Nikon Instruments

第9章 關於我們

The global Cell Culture Market is projected to grow from $33.0 billion in 2025 to $91.3 billion by 2035, at a compound annual growth rate (CAGR) of 10.7%. The cell culture market is driven by the increasing demand for biologics, vaccines, cell-based therapies, and regenerative medicine applications. According to the U.S. FDA CBER CY 2024 Report, the agency strengthened support for the growing field of cell and gene therapies, resulting in 10 new cell and gene therapies for rare diseases approved since the August 2023 reorganization of its Office of Therapeutic Products, highlighting the expanding need for advanced cell culture technologies. Rising adoption of mammalian cell culture systems, bioprocessing platforms, and scalable manufacturing solutions is further accelerating market growth.

The Type segment of the Cell Culture Market includes primary cell culture, secondary cell culture, continuous cell lines, stem cell culture, 3D cell culture, and others. Continuous cell lines and 3D cell culture are among the fastest-growing segments due to their increasing use in biopharmaceutical production, drug discovery, and disease modeling. Continuous cell lines offer scalability, reproducibility, and cost efficiency for large-scale manufacturing, while 3D cell culture provides more accurate physiological models. Stem cell culture is also gaining importance due to rising research in regenerative medicine, tissue engineering, and personalized therapies.

The End User segment of the Cell Culture Market includes pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic laboratories, and others. Pharmaceutical and biotechnology companies dominate due to extensive applications of cell culture in biologics manufacturing, vaccines, gene therapies, and drug development. Academic and research institutes contribute significantly through research in cell biology, cancer studies, and regenerative medicine. Hospitals and diagnostic laboratories are adopting cell culture technologies for clinical testing and disease research. Increasing investments in advanced therapies and precision medicine are further supporting market growth across end-user segments.

Geographical Overview

North America held the largest share of the global cell culture market in 2025, driven by its well-established biotechnology and pharmaceutical industries, advanced research infrastructure, and substantial investments in life sciences. The region is home to leading biopharmaceutical companies, academic research institutions, and contract research organizations that extensively utilize cell culture technologies for drug discovery, vaccine development, regenerative medicine, and biologics manufacturing. Strong government funding for biomedical research, widespread adoption of three-dimensional (3D) cell culture systems, and increasing demand for monoclonal antibodies and cell-based therapies have further strengthened market growth. Additionally, continuous innovation in culture media, bioreactors, and automated cell culture platforms reinforces North America's leadership in the global cell culture market.

Asia Pacific is expected to register the highest growth in the cell culture market due to rapid expansion of the biopharmaceutical sector, increasing investments in biotechnology research, and growing biologics manufacturing capabilities. Countries such as China, India, Japan, South Korea, and Singapore are strengthening their life sciences infrastructure through government-backed initiatives, expanding research facilities, and rising investments in cell therapy, vaccine production, and regenerative medicine. The growing presence of contract development and manufacturing organizations (CDMOs), increasing clinical research activities, and rising demand for biosimilars are further accelerating market expansion. Moreover, lower manufacturing costs, skilled scientific talent, and favorable government policies are expected to position Asia Pacific as the fastest-growing regional market throughout the forecast period.

Key Trends and Drivers

Growing Adoption of 3D Cell Culture and Advanced Cell Culture Technologies:

The Cell Culture Market is witnessing a strong trend toward the adoption of advanced 3D cell culture models, organoids, and microphysiological systems that provide more accurate representations of human biological responses compared with traditional 2D cultures. These technologies are increasingly used in drug discovery, toxicity testing, regenerative medicine, and personalized medicine applications. Pharmaceutical and biotechnology companies are investing in innovative cell culture platforms, including automated bioreactors, serum-free media, and scalable production systems to improve research efficiency and therapeutic manufacturing. The increasing demand for reliable preclinical models and biologics development is accelerating the adoption of next-generation cell culture solutions.

Increasing Demand for Biologics, Cell Therapies, and Vaccine Production:

The rising demand for biologics, cell-based therapies, vaccines, and regenerative medicine products is a major driver of the Cell Culture Market. The expansion of monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies has increased the need for efficient and scalable cell culture systems. Pharmaceutical and biotechnology companies are investing in advanced culture media, single-use bioreactors, and high-throughput cell culture technologies to support large-scale manufacturing. Additionally, growing research activities in cancer biology, stem cell studies, and drug development are further increasing the utilization of cell culture techniques. Expanding biopharmaceutical pipelines and increasing healthcare investments worldwide continue to support market growth.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Equipment
• 2.9 Key Market Highlights by Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Primary Cell Culture
  • 4.1.2 Secondary Cell Culture
  • 4.1.3 Continuous Cell Lines
  • 4.1.4 Stem Cell Culture
  • 4.1.5 3D Cell Culture
  • 4.1.6 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Media
  • 4.2.2 Sera
  • 4.2.3 Reagents
  • 4.2.4 Bioreactors
  • 4.2.5 Culture Systems
  • 4.2.6 Cryopreservation Equipment
  • 4.2.7 Consumables
  • 4.2.8 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Cell Line Development
  • 4.3.2 Cell Banking
  • 4.3.3 Cell Culture Contamination Testing
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 2D Cell Culture
  • 4.4.2 3D Cell Culture
  • 4.4.3 Microcarrier Culture
  • 4.4.4 Perfusion Culture
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Biopharmaceutical Production
  • 4.5.2 Tissue Engineering & Regenerative Medicine
  • 4.5.3 Cancer Research
  • 4.5.4 Gene Therapy
  • 4.5.5 Drug Development
  • 4.5.6 Stem Cell Research
  • 4.5.7 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Pharmaceutical & Biotechnology Companies
  • 4.6.2 Academic & Research Institutes
  • 4.6.3 Hospitals & Diagnostic Laboratories
  • 4.6.4 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Upstream Process
  • 4.7.2 Downstream Process
  • 4.7.3 Others
• 4.8 Market Size & Forecast by Equipment (2020-2035)
  • 4.8.1 Incubators
  • 4.8.2 Centrifuges
  • 4.8.3 Biosafety Cabinets
  • 4.8.4 Pipetting Instruments
  • 4.8.5 Others
• 4.9 Market Size & Forecast by Mode (2020-2035)
  • 4.9.1 Adherent Cell Culture
  • 4.9.2 Suspension Cell Culture
  • 4.9.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Equipment
    • 5.2.1.9 Mode
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Equipment
    • 5.2.2.9 Mode
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Equipment
    • 5.2.3.9 Mode
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Equipment
    • 5.3.1.9 Mode
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Equipment
    • 5.3.2.9 Mode
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Equipment
    • 5.3.3.9 Mode
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Equipment
    • 5.4.1.9 Mode
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Equipment
    • 5.4.2.9 Mode
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Equipment
    • 5.4.3.9 Mode
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Equipment
    • 5.4.4.9 Mode
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Equipment
    • 5.4.5.9 Mode
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Equipment
    • 5.4.6.9 Mode
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Equipment
    • 5.4.7.9 Mode
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Equipment
    • 5.5.1.9 Mode
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Equipment
    • 5.5.2.9 Mode
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Equipment
    • 5.5.3.9 Mode
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Equipment
    • 5.5.4.9 Mode
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Equipment
    • 5.5.5.9 Mode
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Equipment
    • 5.5.6.9 Mode
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Equipment
    • 5.6.1.9 Mode
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Equipment
    • 5.6.2.9 Mode
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Equipment
    • 5.6.3.9 Mode
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Equipment
    • 5.6.4.9 Mode
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Equipment
    • 5.6.5.9 Mode

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Thermo Fisher Scientific
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Merck KGaA
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 GE Healthcare
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Lonza Group
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Corning Incorporated
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Sartorius AG
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Eppendorf AG
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Becton Dickinson and Company
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Danaher Corporation
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Fujifilm Holdings Corporation
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Agilent Technologies
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bio-Rad Laboratories
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Miltenyi Biotec
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Promega Corporation
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Takara Bio
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 HiMedia Laboratories
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 InvivoGen
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 STEMCELL Technologies
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Greiner Bio-One International
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Nikon Instruments
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us